THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
March 07, 2017 07:45 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 07, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading clinical-stage biopharmaceutical company focused on developing therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
March 03, 2017 07:44 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 03, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
February 21, 2017 07:48 ET | Abeona Therapeutics Inc
Company CEO and COO Presentations to be Held on Wednesday, February 22ndNEW YORK and CLEVELAND, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading...
Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposiumâ„¢ 2017
February 17, 2017 07:45 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO):ABO-102 gene therapy well-tolerated in 4 subjects (N=3 low dose, N=1 high dose) through 650 days...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposiumâ„¢ 2017
February 07, 2017 07:45 ET | Abeona Therapeutics Inc
Multiple Oral Platform Presentations and Poster Sessions Highlighting Gene Therapy Programs, Tuesday, February 14th through Thursday, February 16th NEW YORK and CLEVELAND, Feb. 07, 2017 (GLOBE...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A
February 01, 2017 07:43 ET | Abeona Therapeutics Inc
ABO-102, the leading clinical gene therapy program for Sanfilippo syndrome type A patients, has demonstrated central nervous system (CNS) and peripheral organ disease biopotencyFirst high dose cohort...